New results from a human clinical study revealed that LifeVantage Corporation’s MindBody GLP-1 System provides increased fat loss, improved cravings control and healthier body composition. When combining data from this recent clinical trial with another trial conducted in the fall of 2024, the researchers discovered an average increase of GLP-1 to over 200%, compared to the previously reported 140%.
“These findings validate the effectiveness of our natural approach to stimulating the body’s own production of GLP-1 and other key metabolic hormones,” said Lisa Barnes, LifeVantage Vice President of R&D and Regulatory. “The MindBody GLP-1 System and living an activated lifestyle produces meaningful, lasting results–helping people manage cravings, improve self-control, and support sustainable metabolic health naturally. We remain committed to delivering evidence-based innovations that empower health from within.”
Key findings from the US clinical research study showed notable changes to participants’ relationship with food, including a 95% decrease in sugar cravings, an 86% decrease in cravings for salt and soda and an 89% decrease in fast-food cravings. The average weight loss for participants during the 12 weeks was 11 pounds, with some losing up to 25 pounds. Participants also saw an up to 9% decrease in subcutaneous fat and up to 24% decrease in visceral fat. Of this weight loss, 100% was lost from fat, not muscle.
The post LifeVantage Clinical Trial Shows 200% Increase in Natural GLP-1 Production first appeared on Direct Selling News.
